Tuesday, 08 October 2024


China approves two COVID-19 vaccine trials against most recent circulating XBB variants

22 May 2023 | News

According to surveillance data, the primary pandemic variants of COVID-19 virus in China have evolved into XBB series

Image credit: shutterstock

Image credit: shutterstock

Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center, Sichuan University against the most recent circulating XBB variants, have received the "Drug Clinical Trial Approval" from the National Medical Products Administration of China.

These two new vaccines will be quickly commercialised for protecting against the current circulating XBB variant when the necessary clinical trials are completed. These two vaccines are also the first COVID-19 vaccines in the world to begin clinical trials specifically for variants like XBB.

Taking advantage of the rapid response of the internationally advanced insect cell expression platform in recombinant protein vaccine production, WestVac Biopharma and its subsidiary company called WestVac Biopharma(Guangzhou) has constructed the vector for the Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), and produced trivalent recombinant protein vaccines of high purity and high quality for human use.

The subunit vaccine antigen is precisely designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB and BA.5, and can self-assemble into stable trimeric protein particles. Studies have shown that the vaccine induced high titers of neutralising antibodies against multiple subvariants, including Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, indicating that it is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants at home and abroad.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account